This includes lutikizumab (anti-IL1a and IL1b) for osteoarthritis, and COVA322, a bispecific TNF/IL17A antibody fusion protein studied in phase 1/2 in patients with stable chronic moderate-to-severe plaque Pso (stopped for safety reasons). This evidence concerns the gene IL17A and osteoarthritis.